SNSS - サネシス・ファ―マス―ティカルズ (Sunesis Pharmaceuticals Inc.)

SNSSのニュース

   Thinking about buying stock in Vivint Solar, Actinium Pharmaceuticals, Delta Air Lines, Sunesis Pharmaceuticals, or Novan Inc?  2020/07/27 14:45:00 PR Newswire
NEW YORK, July 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VSLR, ATNM, DAL, SNSS, and NOVN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Is Sunesis Pharmaceuticals (SNSS) Stock Outpacing Its Medical Peers This Year?  2020/07/23 15:30:03 Yahoo Finance
Is (SNSS) Outperforming Other Medical Stocks This Year?
   Thinking about buying stock in Sunesis Pharmaceuticals, TOP Ships, Lilis Energy, Seanergy Maritime Holdings, or Plug Power?  2020/06/23 14:30:00 PR Newswire
NEW YORK, June 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNSS, TOPS, LLEX, SHIP, and PLUG. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Sunesis Pharmaceuticals Announces Clinical Update on Vecabrutinib Program  2020/06/23 11:30:00 GlobeNewswire
Company Shifting Resources from Vecabrutinib to Development of PDK-1 Inhibitor SNS-510
   Is Sunesis Pharmaceuticals (SNSS) Stock Outpacing Its Medical Peers This Year?  2020/04/02 15:30:10 Zacks Investment Research
Is (SNSS) Outperforming Other Medical Stocks This Year?
   Is Sunesis Pharmaceuticals (SNSS) Stock Outpacing Its Medical Peers This Year?  2020/04/02 15:30:10 Zacks Investment Research
Is (SNSS) Outperforming Other Medical Stocks This Year?
   Is Sunesis Pharmaceuticals (SNSS) Outperforming Other Medical Stocks This Year?  2020/03/17 15:30:10 Zacks Investment Research
Is (SNSS) Outperforming Other Medical Stocks This Year?
   Sunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q4 2019 Results - Earnings Call Transcript  2020/03/10 23:38:39 Seeking Alpha
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Q4 2019 Results Earnings Conference Call March 10, 2020, 4:30 pm ET Company Participants Willie Quinn - Chief Financ
   Sunesis Pharmaceuticals (NASDAQ:SNSS) Lifted to “Buy” at Zacks Investment Research  2019/11/16 16:24:33 Modern Readers
Sunesis Pharmaceuticals (NASDAQ:SNSS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday, Zacks.com reports. The brokerage currently has a $0.50 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 35.14% […]
   Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Short Interest Update  2019/11/14 14:15:40 Modern Readers
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 1,130,000 shares, a growth of 408.3% from the September 30th total of 222,300 shares. Approximately 1.8% of the shares of the company are sold short. Based on an average trading […]
   Is Sunesis Pharmaceuticals (SNSS) Stock Outpacing Its Medical Peers This Year?  2020/04/02 15:30:10 Zacks Investment Research
Is (SNSS) Outperforming Other Medical Stocks This Year?
   Is Sunesis Pharmaceuticals (SNSS) Outperforming Other Medical Stocks This Year?  2020/03/17 15:30:10 Zacks Investment Research
Is (SNSS) Outperforming Other Medical Stocks This Year?
   Sunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q4 2019 Results - Earnings Call Transcript  2020/03/10 23:38:39 Seeking Alpha
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Q4 2019 Results Earnings Conference Call March 10, 2020, 4:30 pm ET Company Participants Willie Quinn - Chief Financ
   Sunesis Pharmaceuticals (NASDAQ:SNSS) Lifted to “Buy” at Zacks Investment Research  2019/11/16 16:24:33 Modern Readers
Sunesis Pharmaceuticals (NASDAQ:SNSS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday, Zacks.com reports. The brokerage currently has a $0.50 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 35.14% […]
   Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Short Interest Update  2019/11/14 14:15:40 Modern Readers
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 1,130,000 shares, a growth of 408.3% from the September 30th total of 222,300 shares. Approximately 1.8% of the shares of the company are sold short. Based on an average trading […]

calendar